Skip to navigation Skip to content

Clinical Trial: Higher dose of ocrelizumab in PPMS


Type of MS: PPMS
Treatment mode of action: To increase time to progression
Number of Subjects: 4
Medication: ocrelizumab
Location: California
Institutions: SC3 Research - Pasadena
50 Alessandro Pl, Pasadena, CA 91105 Contact Information
Roxanne Cabading, x799
(626) 250 2070


F. Hoffman-La Roche Ltd


An open-label, single-arm study to evaluate the effectiveness and safety of ocrelizumab in people with primary progressive MS. Subjects participating in the study will complete the following procedures: study visits, blood draw/sample collections, MRI Scans, potential lumbar punctures, medical history review, vital sign collection and physical/neurological examination, urine sample/pregnancy testing and questionnaire completion. 


© 2022 The National Multiple Sclerosis Society is a tax exempt 501(c)3 nonprofit organization. Its Identification Number (EIN) is 13-5661935.